Administering Bharat Biotech's COVAXIN, a move cheered by nationalist
politicians, has worried some health experts who consider it rushed,
as the vaccine has only limited, "clinical-trial mode" approval. In
addition to efficacy concerns, the close monitoring required for its
use will be a massive challenge in a country of 1.35 billion people.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/india-to-treat-homegrown-covid-19-vaccine-same-as-astrazenecas/articleshow/80269109.cms
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment